The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Open accessAbstract
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. METHODS: In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart. RESULTS: Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, P=0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern. CONCLUSIONS: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of CATT participants (>92%) had stable or improved VA relative to baseline.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Comparison of AMD Treatments Trials (CATT) showed that bevacizumab was equivalent to ranibizumab in improving visual acuity (VA) of patients with neovascular AMD when treatment was administered either monthly or pro re nata (PRN).1”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“However, despite this remarkable clinical effect, there was a wide range in treatment response.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“At one year, participants treated monthly with bevacizumab or ranibizumab gained 8.0 and 8.5 letters, respectively, and those treated as needed gained 5.9 and 6.8 letters, respectively.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. L. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,147
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,134
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
Cited by
Sorted by citations
Items 101–200 of 1,009
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Moja, L., Lucenteforte, E., Kwag, K. H., Bertelè, V., Campomori, A., Chakravarthy, U., D’Amico, R., Dickersin, K., Kodjikian, L., Lindsley, K. B., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011230.pub2 · Cited by 190
Krebs, I., Schmetterer, L. F., Boltz, A., Told, R., Vécsei-Marlovits, V. P., Egger, S. F., Schönherr, U., Haas, A., Ansari‐Shahrezaei, S., & Binder, S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-302391 · Cited by 191
Holz, F. G., Dugel, P. U., Weissgerber, G., Hamilton, R., Silva, R., Bandello, F., Larsen, M., Weichselberger, A., Wenzel, A., Schmidt, A., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.12.030 · Cited by 184
Anti-vascular endothelial growth factor for diabetic macular oedema
Virgili, G., Parravano, M., Menchini, F., & Evans, J. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub4 · Cited by 188
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Virgili, G., Parravano, M., Evans, J. R., Gordon, I., & Lucenteforte, E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub6 · Cited by 183
Arnold, J., Campain, A. E., Barthelmes, D., Simpson, J. M., Guymer, R. H., Hunyor, A. P., McAllister, I. L., Essex, R. W., Morlet, N., Gillies, M. C., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.02.009 · Cited by 179
STEVENSON, W. C., Cheng, S.-F., Dastjerdi, M. H., Ferrari, G., & Dana, R. (2012) · The Ocular Surface · doi:10.1016/j.jtos.2012.01.005 · Cited by 185
Deep Learning of the Retina Enables Phenome- and Genome-Wide Analyses of the Microvasculature
Zekavat, S. M., Raghu, V. K., Trinder, M., Ye, Y., Koyama, S., Honigberg, M. C., Yu, Z., Pampana, A., Urbut, S., Haidermota, S., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.057709 · Cited by 181
Age‐related macular degeneration—clinical review and genetics update
Ratnapriya, R., & Chew, E. Y. (2013) · Clinical Genetics · doi:10.1111/cge.12206 · Cited by 180
Targeting VEGF in eye neovascularization: What's new?
Amadio, M., Govoni, S. M., & Pascale, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.027 · Cited by 180
Progress on retinal image analysis for age related macular degeneration
Kanagasingam, Y., Bhuiyan, A., Abràmoff, M. D., Smith, R. T., Goldschmidt, L. P., & Wong, T. Y. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.10.002 · Cited by 178
Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options
Wallsh, J. O., & Gallemore, R. P. (2021) · Cells · doi:10.3390/cells10051049 · Cited by 170
Development of human embryonic stem cell therapies for age-related macular degeneration
Carr, A. F., Smart, M. J. K., Ramsden, C. M., Powner, M. B., da Cruz, L., & Coffey, P. J. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.03.006 · Cited by 169
Management of high-risk corneal transplantation
Zazzo, A. D., Kheirkhah, A., Abud, T. B., Goyal, S., & Dana, R. (2016) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2016.12.010 · Cited by 168
Bakri, S. J., Thorne, J. E., Ho, A. C., Ehlers, J. P., Schoenberger, S. D., Yeh, S., & Kim, S. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.028 · Cited by 173
Liu, B., Wei, L., Meyerle, C., Tuo, J., Sen, H. N., Li, Z., Chakrabarty, S., Agron, E., Chan, C.-C., Klein, M. L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-111 · Cited by 164
Querques, G., Srour, M., Massamba, N., Georges, A., Moussa, N. B., Rafaeli, O., & Souied, E. H. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-11665 · Cited by 166
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081786 · Cited by 161
Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degenerationPreprint
Kim, K., Park, S. W., Kim, J. H., Lee, S. H., Kim, D., Koo, T., Kim, K.-E., Kim, J. H., & Kim, J. (2017) · Genome Research · doi:10.1101/gr.219089.116 · Cited by 170
Carnevali, A., Cicinelli, M. V., Capuano, V., Corvi, F., Mazzaferro, A., Querques, L., Scorcia, V., Souied, E. H., Bandello, F. M., & Querques, G. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.06.042 · Cited by 162
Tutorial on Biostatistics: Linear Regression Analysis of Continuous Correlated Eye Data
Ying, G., Maguire, M. G., Glynn, R. J., & ROSNER, B. A. (2017) · Ophthalmic Epidemiology · doi:10.1080/09286586.2016.1259636 · Cited by 162
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
Cho, H., Shah, C. P., Weber, M., & Heier, J. S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303344 · Cited by 161
Wecker, T., Ehlken, C., Bühler, A., Lange, C., Agostini, H. T., Böhringer, D., & Stahl, A. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308668 · Cited by 159
Liu, K., Song, Y., Xu, G., Ye, J., Wu, Z., Liu, X., Dong, X.-G., Zhang, M., Xing, Y., Zhu, S., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.08.026 · Cited by 160
Zehetner, C., Kirchmair, R., Huber, S., Kralinger, M. T., & Kieselbach, G. F. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-302451 · Cited by 158
Viiri, J., Amadio, M., Marchesi, N., Hyttinen, J. M. T., Kivinen, N., Sironen, R., Rilla, K., Akhtar, S., Provenzani, A., D'Agostino, V. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069563 · Cited by 145
Treatment of diabetic retinopathy: Recent advances and unresolved challenges
Stewart, M. W. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i16.333 · Cited by 166
Injectable hydrogels for ophthalmic applications
Wang, K., & Han, Z. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.031 · Cited by 158
An Outbreak of Streptococcus Endophthalmitis After Intravitreal Injection of Bevacizumab
Goldberg, R. A., Flynn, H. W., Isom, R. F., Miller, D., & Gonzalez, S. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.11.035 · Cited by 156
Schmidt-Erfurth, U. M., Vogl, W., Jampol, L. M., & Bogunović, H. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.010 · Cited by 159
Constable, I. J., Pierce, C. M., Lai, C.-M., Magno, A. L., Degli-Esposti, M. A., French, M. A., McAllister, I. L., Butler, S., Barone, S. B., Schwartz, S. D., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.016 · Cited by 152
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
A systems biology view of blood vessel growth and remodelling
Logsdon, E. A., Finley, S. D., Popel, A. S., & Gabhann, F. M. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12164 · Cited by 163
EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASES
Gillies, M. C., Walton, R., Liong, J., Arnold, J., McAllister, I. L., Morlet, N., Hunyor, A. P., Guymer, R. H., Keeffe, J., Essex, R. W., et al. (2013) · Retina · doi:10.1097/iae.0b013e318296b271 · Cited by 151
Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related Macular Degeneration
Chang, A., Li, H., Broadhead, G., Hong, T., Schlub, T. E., Wijeyakumar, W., & Zhu, M. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.035 · Cited by 152
TRIM21—From Intracellular Immunity to Therapy
Foss, S., Bottermann, M., Jonsson, A., Sandlie, I., James, L. C., & Andersen, J. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02049 · Cited by 156
Age-Related Macular Degeneration: Advances in Management and Diagnosis
Yonekawa, Y., Miller, J. W., & Kim, I. K. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4020343 · Cited by 153
Oishi, A., Kojima, H., Mandai, M., Honda, S., Matsuoka, T., Oh, H., Kita, M., Nagai, T., Fujihara, M., Bessho, N., et al. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.024 · Cited by 150
Reticular pseudodrusen: A critical phenotype in age-related macular degeneration
Wu, Z., Fletcher, E. L., Kumar, H., Greferath, U., & Guymer, R. H. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101017 · Cited by 147
Venhuizen, F. G., van Ginneken, B., Liefers, B. J., van Asten, F., Schreur, V., Fauser, S., Hoyng, C. B., Theelen, T., & Sánchez, C. I. (2018) · Biomedical Optics Express · doi:10.1364/boe.9.001545 · Cited by 146
Evans, R. N., Reeves, B. C., Maguire, M. G., Martin, D. F., Muldrew, A., Peto, T., Rogers, C., & Chakravarthy, U. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.3001 · Cited by 145
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
Haug, S. J., Hien, D. L., Uludag, G., Ngoc, T. T. T., Lajevardi, S., Halim, M. S., Sepah, Y. J., Do, D. V., & Khanani, A. M. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100680 · Cited by 142
Hormel, T. T., Jia, Y., Jian, Y., Hwang, T. S., Bailey, S. T., Pennesi, M. E., Wilson, D. J., Morrison, J. C., & Huang, D. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100878 · Cited by 149
Tian, Y., Zhang, F., Qiu, Y., Wang, S., Li, F., Zhao, J., Pan, C., Tao, Y. K., Yu, D., & Wei, W. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00764-3 · Cited by 148
Lim, J. H., Wickremasinghe, S. S., Xie, J., Chauhan, D. S., Baird, P. N., Robman, L. D., Hageman, G., & Guymer, R. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.09.013 · Cited by 141
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142
“The Comparison of AMD Treatments Trials (CATT) showed that bevacizumab was equivalent to ranibizumab in improving visual acuity (VA) of patients with neovascular AMD when treatment was administered either monthly or pro re nata (PRN).(1) At 1 year, participants treated monthly with bevacizumab or ranibizumab gained r”
InfluentialAflibercept for neovascular age-related macular degeneration
Sarwar, S., Clearfield, E., Soliman, M. K., Sadiq, M. A., Baldwin, A. J., Hanout, M., Agarwal, A., Sepah, Y. J., Do, D. V., & Nguyen, Q. D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011346.pub2 · Cited by 142
Cerani, A., Tetreault, N., Ménard, C., Lapalme, E., Patel, C., Sitaras, N., Beaudoin, F., Leboeuf, D., Guire, V. D., Binet, F., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.003 · Cited by 147
Cheung, N., Wong, I. Y., & Wong, T. Y. (2014) · Diabetes Care · doi:10.2337/dc13-1990 · Cited by 149
Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration
Sadda, S. R., Tuomi, L. L., Ding, B., Fung, A. E., & Hopkins, J. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.12.026 · Cited by 155
Anti-VEGF therapy in pituitary carcinoma
Ortiz, L. D., Syro, L. V., Scheithauer, B. W., Erşen, A., Uribe, H., Fadul, C. E., Rotondo, F., Horváth, É., & Kovács, K. (2011) · Pituitary · doi:10.1007/s11102-011-0346-8 · Cited by 141
Li, E., Donati, S., Lindsley, K. B., Krzystolik, M. G., & Virgili, G. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012208.pub2 · Cited by 143
van Geest, R. J., Oberstein, S. Y. L., Tan, H. S., Mura, M., Goldschmeding, R., Noorden, C. J. F. V., Klaassen, I., & Schlingemann, R. O. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2012.4723.x · Cited by 141
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Niwa, Y., Kakinoki, M., Sawada, T., Wang, X., & Ohji, M. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17279 · Cited by 143
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
Stewart, M. W. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300654 · Cited by 142
Aflibercept for Age-Related Macular Degeneration: A Game-Changer or Quiet Addition?
Browning, D. J., Kaiser, P. K., Rosenfeld, P. J., & Stewart, M. W. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.04.020 · Cited by 140
Huang, D., Jia, Y., Rispoli, M., Tan, O., & Lumbroso, B. D. (2015) · Retina · doi:10.1097/iae.0000000000000846 · Cited by 137
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
VANDER, J. F. (2012) · Yearbook of Ophthalmology · doi:10.1016/j.yoph.2011.12.002 · Cited by 138
A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
Schmucker, C. M., Ehlken, C., Agostini, H., Antes, G., Rücker, G., Lelgemann, M., & Loke, Y. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042701 · Cited by 139
CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION
Vélez-Montoya, R., Oliver, S. C. N., Olson, J. L., Fine, S. L., Quiroz-Mercado, H., & Mandava, N. (2013) · Retina · doi:10.1097/iae.0000000000000036 · Cited by 141
Aflibercept in wet AMD: specific role and optimal use
Semeraro, F., Morescalchi, Duse, S., Parmeggiani, F., Gambicorti, & Costagliola, C. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s40215 · Cited by 138
Age-related macular degeneration: genome-wide association studies to translation
Black, J. R., & Clark, S. J. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.70 · Cited by 139
Ranibizumab for the treatment of wet AMD: a summary of real-world studies
Chong, V. N. (2015) · Eye · doi:10.1038/eye.2015.217 · Cited by 140
Rao, P., Lum, F., Wood, K., Salman, C., Burugapalli, B., Hall, R. M., Singh, S., Parke, D. W., & Williams, G. A. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.10.010 · Cited by 137
Mechanism of Inflammation in Age-Related Macular Degeneration
Parmeggiani, F., Romano, M., Costagliola, C., Semeraro, F., Incorvaia, C., D’Angelo, S., Perri, P., Palma, P. D., Nadai, K. D., & Sebastiani, A. (2012) · Mediators of Inflammation · doi:10.1155/2012/546786 · Cited by 140
Therapeutic implications of nanomedicine for ocular drug delivery
Meng, T., Kulkarni, V. R., Simmers, R., Brar, V. S., & Xu, Q. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.006 · Cited by 135
Antoszyk, A. N., Glassman, A. R., Beaulieu, W. T., Jampol, L. M., Jhaveri, C. D., Punjabi, O. S., Salehi-Had, H., Wells, J. A., Maguire, M. G., Stockdale, C. R., et al. (2020) · JAMA · doi:10.1001/jama.2020.23027 · Cited by 132
Mandel, Y., Goetz, G. A., Lavinsky, D., Huie, P., Mathieson, K., Wang, L., Kamins, T. I., Galambos, L., Manivanh, R. V., Harris, J. S., et al. (2013) · Nature Communications · doi:10.1038/ncomms2980 · Cited by 131
Sahni, J., Dugel, P. U., Patel, S. S., Chittum, M. E., Berger, B., del Valle Rubido, M., Sadikhov, S., Szczesny, P., Schwab, D., Nogoceke, E., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2685 · Cited by 129
Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye
Sène, A., Chin-Yee, D., & Apte, R. S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.005 · Cited by 130
Anti–Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease
Campochiaro, P. A., Aiello, L. P., & Rosenfeld, P. J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.04.056 · Cited by 136
Rohm, M., Tresp, V., Müller, M., Kern, C., Manakov, I., Weiss, M., Sim, D. A., Priglinger, S. G., Keane, P. A., & Kortuem, K. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.12.034 · Cited by 129
The suprachoroidal space as a route of administration to the posterior segment of the eye
Chiang, B., Jung, J. H., & Prausnitz, M. R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.001 · Cited by 134
Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning
Moraes, G., Fu, D. J., Wilson, M., Khalid, H., Wagner, S. K., Korot, E., Ferraz, D., Faes, L., Kelly, C. J., Spitz, T., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.09.025 · Cited by 130
Role of diet and food intake in age‐related macular degeneration: a systematic review
Chapman, N. A., Jacobs, R. J., & Braakhuis, A. J. (2018) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13343 · Cited by 129
Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases
Campochiaro, P. A., & Akhlaq, A. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100921 · Cited by 130
Small, K. W., DeLuca, A. P., Whitmore, S. S., Rosenberg, T., Silva-Garcia, R., Udar, N., Puech, B., GARCIA, C. A., Rice, T. A., Fishman, G. A., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.006 · Cited by 128
ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATION
Abedi, F., Wickremasinghe, S., Islam, A. F. M., Inglis, K. M., & Guymer, R. H. (2014) · Retina · doi:10.1097/iae.0000000000000134 · Cited by 125
Thulliez, M., Angoulvant, D., Lez, M. L., Jonville‐Béra, A. ‐., Pisella, P., Gueyffier, F., & Bejan‐Angoulvant, T. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.2333 · Cited by 125
Wykoff, C. C., Clark, W. L., Nielsen, J. S., Brill, J. V., Greene, L. S., & Heggen, C. L. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.2-a.s3 · Cited by 127
Anti-VEGF Therapy and the Retina: An Update
Tah, V., Orlans, H. O., Hyer, J. N., Casswell, E. J., Din, N., Shanmuganathan, V. S., Ramskold, L., & Pasu, S. (2015) · Journal of Ophthalmology · doi:10.1155/2015/627674 · Cited by 130
Automated Staging of Age-Related Macular Degeneration Using Optical Coherence Tomography
Venhuizen, F. G., van Ginneken, B., van Asten, F., van Grinsven, M. J. J. P., Fauser, S., Hoyng, C. B., Theelen, T., & Sánchez, C. I. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20541 · Cited by 128
Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration
Larsen, M., Schmidt-Erfurth, U. M., Lanzetta, P., Wolf, S., Simader, C., Tokaji, E., Pilz, S., & Weisberger, A. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.002 · Cited by 126
Khanna, S., Komati, R., Eichenbaum, D. A., Hariprasad, I., Ciulla, T. A., & Hariprasad, S. M. (2019) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2019-000398 · Cited by 128
INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY
Chen, S.-N., Lian, I., Hwang, Y.-C., Chen, Y., Chang, Y.-C., Lee, K.-H., Chuang, C., & Wu, W. (2014) · Retina · doi:10.1097/iae.0000000000000380 · Cited by 123
Extended Release of Bevacizumab by Thermosensitive Biodegradable and Biocompatible Hydrogel
Wang, C., Hwang, Y., Chiang, P.-R., Shen, C., Hong, W.-H., & Hsiue, G. (2011) · Biomacromolecules · doi:10.1021/bm2009558 · Cited by 124
Krebs, I., Glittenberg, C. G., Ansari‐Shahrezaei, S., Hagen, S., Steiner, I., & Binder, S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303513 · Cited by 126
Inflammatory Complications of Intravitreal Anti-VEGF Injections
Cox, J. T., Eliott, D., & Sobrin, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050981 · Cited by 131
Are we there yet? Bevacizumab therapy for retinopathy of prematurity
Darlow, B. A., Ells, A. L., Gilbert, C. E., Gole, G. A., & Quinn, G. E. (2011) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/archdischild-2011-301148 · Cited by 119
Age‐Related Macular Degeneration
Cheung, L. K., & Eaton, A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1264 · Cited by 130
Management of pseudophakic cystoid macular edema
Guo, S., Patel, S. N., Baumrind, B. R., Johnson, K. S., Levinsohn, D., Marcus, E., Tannen, B. L., Roy, M. S., Bhagat, N., & Zarbin, M. A. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.08.005 · Cited by 120
van Asten, F., Michels, C. T. J., Hoyng, C. B., van der Wilt, G. J., Klevering, B. J., Rovers, M. M., & Grutters, J. P. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197670 · Cited by 121
Bressler, N. M., Doan, Q. V., Varma, R., Lee, P. P., Suñer, I. J., Dolan, C., Danese, M. D., Yu, E., Tran, I., & Colman, S. S. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.140 · Cited by 120
Fit for the Eye: Aptamers in Ocular Disorders
Drolet, D. W., Green, L. S., Gold, L., & Janjić, N. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0573 · Cited by 123
Liposomes for effective drug delivery to the ocular posterior chamber
Lai, S., Wei, Y., Wu, Q., Zhou, K., Liu, T., Zhang, Y., Jiang, N., Xiao, W. F., Chen, J., Liu, Q., et al. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0498-7 · Cited by 121
Time Trends in the Incidence and Causes of Blindness in Israel
Skaat, A., Chetrit, A., Belkin, M., Kinori, M., & Kalter-Leibovici, O. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.035 · Cited by 115
Daniel, E., Pan, W., Ying, G.-S., Kim, B. J., Grunwald, J. E., Ferris, F. L., Jaffe, G. J., Toth, C. A., Martin, D. F., Fine, S. L., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.01.004 · Cited by 119
Cheung, C. M. G., & Wong, T. Y. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12227 · Cited by 122
Doyle, S., Ozaki, E., Brennan, K., Humphries, M. M., Mulfaul, K., Keaney, J., Kenna, P. F., Maminishkis, A., Kiang, A., Saunders, S. P., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007616 · Cited by 116
Metadata
- Authors
- The CATT Research Group
- Corresponding author
- The CATT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-19
- Volume
- 364
- Issue
- 20
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3157322
- OpenAlex
- W1481978003
- Cited by
- 2,669
- References
- 21
- Citations by year
- 2026: 78 · 2025: 91 · 2024: 116 · 2023: 111 · 2022: 127 · 2021: 164 · 2020: 195 · 2019: 151 · 2018: 168 · 2017: 177 · 2016: 199 · 2015: 238 · 2014: 264 · 2013: 248 · 2012: 265
- FWCI
- 254.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10EY017825, U10EY017826, U10EY017823, U10EY017828)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, ranibizumab, bevacizumab, intravitreal injection, anti-VEGF therapy, visual acuity, central retinal thickness, treatment schedule, non-inferiority, serious adverse events, off-label drug use, anti-angiogenic therapy, comparative efficacy and safety, hospitalization
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cardiovascular Diseases, Drug Administration Schedule, Female, Humans, Macular Degeneration, Male, Middle Aged, Retina, Therapeutic Equivalency, Visual Acuity, Proportional Hazards Models, Single-Blind Method, Off-Label Use, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
